Impact of disease volume on survival efficacy of triplet therapy for metastatic hormone-sensitive prostate cancer: a systematic review, meta-analysis, and network meta-analysis

CONCLUSIONS: Triplet therapy improves OS in mHSPC patients compared to docetaxel-based doublet therapy, irrespective of disease volume. However, based on treatment ranking, triplet therapy should preferably be considered for patients with high-volume mHSPC while those with low-volume are likely to be adequately treated with ARSI + ADT.PMID:38582807 | DOI:10.1007/s10147-024-02485-4

Source: Clinical Prostate Cancer - April 6, 2024 Category: Cancer & Oncology Authors: Akihiro Matsukawa Pawel Rajwa Tatsushi Kawada Kensuke Bekku Ekaterina Laukhtina Jakob Klemm Benjamin Pradere Keiichiro Mori Pierre I Karakiewicz Takahiro Kimura Piotr Chlosta Shahrokh F Shariat Takafumi Yanagisawa Source Type: research